Cancer Drug Endpoints: More Standardization Needed In ctDNA Assessments, US FDA Says

 
• By Sue Sutter
Boats at dock
More standardization of circulating tumor DNA assessments has the potential to raise all boats in cancer drug development. • Source: Shutterstock

More from Clinical Trials

More from R&D